Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial

Potential therapeutic approaches in coronavirus disease 2019 (COVID-19) comprise antiviral and immunomodulatory agents; however, no immunomodulator drug has been approved. This multicenter, prospective, open-label, uncontrolled study aimed to assess the use of subcutaneous tocilizumab in adult patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Malekzadeh, Reza, Abedini, Atefeh, Mohsenpour, Behzad, Sharifipour, Ehsan, Ghasemian, Roya, Javad-Mousavi, Seyed Ali, Khodashahi, Rozita, Darban, Mahboobeh, Kalantari, Saeed, Abdollahi, Nafiseh, Salehi, Mohammad Reza, Rezaei Hosseinabadi, Abbas, Khorvash, Farzin, Valizadeh, Melika, Dastan, Farzaneh, Yousefian, Sahar, Hosseini, Hamed, Anjidani, Nassim, Tabarsi, Payam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553010/
https://www.ncbi.nlm.nih.gov/pubmed/33075713
http://dx.doi.org/10.1016/j.intimp.2020.107102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553010/
https://www.ncbi.nlm.nih.gov/pubmed/33075713
http://dx.doi.org/10.1016/j.intimp.2020.107102

Ejemplares similares